세계 항생물질 내성 시장 : 규모, 점유율, 동향 분석 보고서 -질환별, 병원체별, 약제 클래스별, 작용기전별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Antibiotic Resistance Market Growth & Trends:

The global antibiotic resistance market size is expected to reach USD 12.48 billion by 2030, registering a CAGR of 5.27% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of antibiotic-resistant infections due to misuse or overuse of antibiotics is a major factor attributing to market growth. Moreover, the increasing patient base across the globe and high costs associated with the treatment of diseases is anticipated to boost the market growth over the forecast period.

The prevalence of gram-negative infections is increasing at an alarming rate. These infections have lesser treatment options available in the market. The high unmet needs result in high demand for new therapies and, therefore, small and medium-sized pharmaceutical companies are actively involved in the development of novel treatment options. Moreover, the government and other organizations are also aiding research activities to drive the development of innovative therapies.

Multiple mid-level biotechnology companies have entered the arena with targeted therapies for antibiotic-resistant infections. Various manufacturers are developing therapies, especially for drug-resistant infections, that target a smaller population subset.

The U.S. government in alliance with BARDA is supporting several companies to boost the development of new therapies for antibiotic-resistant diseases. BARDA has also been associated with pharmaceutical companies such as GSK; Tetraphase; Basilea; Astra Zeneca; and many more. Many countries and international organizations have formed dedicated groups or alliances to monitor and study the pattern of drug-resistant infections.

For instance, the WHO has introduced the Global Antimicrobial Resistance Surveillance System (GLASS) to monitor antibiotic-resistant infections at a global level. Similarly, the Public Health Agency of Canada has introduced the Canadian Antimicrobial Resistance Surveillance System (CARSS) to study drug-resistant infections pattern at the country level.

However, according to a review published by WHO in March 2023, the antibiotics pipeline activities are limited, with only 12 new antibiotics being approved between 2017 and 2021. The review further stated that there are only 27 new candidates under development, out of which only 6 are considered "innovative" enough to be capable of overcoming antibiotic resistance as defined by WHO.

Antibiotic Resistance Market Report Highlights:

• In 2023, cUTI accounted for the largest market share and is anticipated to maintain its dominance in the global market in the coming years
• Combination drugs are expected to grow at the fastest CAGR over the forecast period
• North America dominated the antibiotic resistance industry in 2023. The target goals set by the U.S. national action plan in response to the significant burden of resistant gram-positive and negative infections is the key factor driving the market
• Asia Pacific is set to witness the fastest growth over the forecast period due to excessive consumption of antibiotics, advancements in technology, and growing awareness about antibiotic resistance testing, treatment, & management of the same.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Pathogen
  • 1.2.3. Drug Class
  • 1.2.4. Mechanism of Action
  • 1.2.5. Distribution Channel
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary Distribution Channels
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Distribution Channels
• 1.9. List of Primary Distribution Channels
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease
  • 2.2.2. Pathogen
  • 2.2.3. Drug Class
  • 2.2.4. Mechanism of Action
  • 2.2.5. Distribution Channel
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Antibiotic Resistance Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing burden of antibiotic-resistant infections
    • 3.2.1.2. Growing need for new antibiotic therapies
    • 3.2.1.3. Rising public health concern and awareness
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of therapeutics
• 3.3. Antibiotic Resistance Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Antibiotic Resistance Market: Disease Estimates & Trend Analysis

• 4.1. Disease Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Antibiotic Resistance Market by Disease Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. cUTI (Complicated Urinary Tract Infections)
    • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. CDI (Clostridioides difficile Infection)
    • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. ABSSSI (Acute bacterial skin and skin structure infections)
    • 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. HABP (Hospital-acquired bacterial pneumonia)
    • 4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. CABP (Community-acquired pneumonia)
    • 4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. cIAI (Complicated intra-abdominal infection)
    • 4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.7. BSI (Bloodstream infection
    • 4.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis

• 5.1. Pathogen Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Antibiotic Resistance Market by Pathogen Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. E. coli
    • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. K. pneumoniae
    • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. P. aeruginosa
    • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.4. S. aureus
    • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.5. A. baumannii
    • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.6. S. pneumoniae
    • 5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.7. H. influenzae
    • 5.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.8. C. difficile
    • 5.4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.9. E. faecium
    • 5.4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis

• 6.1. Drug Class Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Antibiotic Resistance Market by Drug Class Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Oxazolidinones
    • 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 6.4.2. Lipoglycopeptides
    • 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.3. Tetracyclines
    • 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.4. Combination therapies
    • 6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.5. Cephalosporins
    • 6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis

• 7.1. Mechanism of Action Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Antibiotic Resistance Market by Mechanism of Action Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Protein Synthesis Inhibitors
    • 7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 7.4.2. Cell Wall Synthesis Inhibitors
    • 7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. RNA Synthesis Inhibitors
    • 7.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 7.4.4. DNA Synthesis Inhibitors
    • 7.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Others
    • 7.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Distribution Channel Market Share, 2023 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Antibiotic Resistance Market by Distribution Channel Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Hospital Pharmacies
    • 8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 8.4.2. Retail Pharmacies
    • 8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.3. Online Pharmacies
    • 8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Antibiotic Resistance Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. U.S.
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5.2. Canada
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. UK
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.2. Germany
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.3. France
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.4. Italy
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.5. Spain
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.6. Norway
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.7. Sweden
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6.8. Denmark
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/reimbursement structure
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Japan
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.2. China
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.3. India
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.4. Australia
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.5. South Korea
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/reimbursement structure
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7.6. Thailand
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/reimbursement structure
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Brazil
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.2. Mexico
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/reimbursement structure
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. South Africa
    • 9.9.1.1. Key country dynamics
    • 9.9.1.2. Regulatory framework/reimbursement structure
    • 9.9.1.3. Competitive scenario
    • 9.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9.2. Saudi Arabia
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/reimbursement structure
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9.3. UAE
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/reimbursement structure
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9.4. Kuwait
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/reimbursement structure
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2023
  • 10.3.4. Melinta Therapeutics
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Disease benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Basilea Pharmaceutica Ltd.
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Disease benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Tetraphase Pharmaceuticals
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Disease benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Theravance Biopharma
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Disease benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. WOCKHARDT
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Disease benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Paratek Pharmaceuticals, Inc.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Disease benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Seres Therapeutics
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Disease benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. ACHAOGEN, INC.
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Disease benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Entasis therapeutics
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Disease benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. AbbVie
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Disease benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Merck & Co. Inc.
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Disease benchmarking
    • 10.3.14.4. Strategic initiatives